HER2 mutation is a rare but critical oncogenic driver associated with resistance to traditional therapies among NSCLC subtypes, including chemotherapy and tyrosine kinase inhibitors (TKIs). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.